COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2022-000617-13-ES


Column Value
Trial registration number EUCTR2022-000617-13-ES
Full text link
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

First author
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Hospital Universitari Vall d'Hebron - Oriol Bestard

Contact
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

obestard@vhebron.net

Registration date
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

2022-03-04

Recruitment status
Last imported at : June 11, 2024, 8 p.m.
Source : EU Clinical Trials Register

Completed

Study design
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Open label

Center
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

multi-center

Study aim
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Prevention

Inclusion criteria
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

1. Patient’s age ≥ 18 years 2. Time of transplantation ≥ 1 year 3. Negative or very weak (<143BAU/ml) serological immune response after 3 doses of an mRNA SARS-CoV-2 vaccine 4. Stable renal function with an estimated GFR ≥ 40 mL/min/1.73 m2 5. Urine protein to creatinine ratio < 0.8 g/g 6. Written informed consent 1. Edad del paciente ≥ 18 años 2. Tiempo de trasplante ≥ 1 año 3. Respuesta inmune serológica negativa o muy débil (<143BAU/ml) después de 3 dosis de una vacuna de ARNm SARS-CoV-2 4. Función renal estable con FG estimado ≥ 40 ml/min/1,73 m2 5. Proporción de proteína en orina a creatinina < 0,8 g/g 6. Consentimiento informado por escrito

Exclusion criteria
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

1. Previous diagnosis of T-cell mediated or antibody-mediated rejection 2. Previous seroconversion after any SARS-CoV-2 vaccine. 3. Previous COVID-19 infection 4. Presence of HLA donor-specific antibodies 5. Active cancer excluding non-melanoma skin cancer 6. Pregnancy 1. Diagnóstico previo de rechazo mediado por células T o mediado por anticuerpos 2. Seroconversión previa después de cualquier vacuna contra el SARS-CoV-2. 3. Infección previa por COVID-19 4. Presencia de anticuerpos específicos del donante HLA 5. Cáncer activo excluyendo el cáncer de piel no melanoma 6. Embarazo

Number of arms
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)

Inclusion age min
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

100

Countries
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Spain

Type of patients
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

High risk patients

Severity scale
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

N/A

Total sample size
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

50

primary outcome
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Difference in the percentage of patients with a positive humoral immune response one month after the 4th dose of the mRNA SARS-CoV-2 vaccine between groups. Diferencia en el porcentaje de pacientes con respuesta inmune humoral positiva al mes de la 4ª dosis de la vacuna mRNA SARS-CoV-2 entre grupos.

Notes
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Declared number of arm (2.0) differs from found arms (3.0)

Phase
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Phase 4

Arms
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

[{"arm_notes": "New Type treatment : mycophenolate mofetil", "treatment_id": 2169, "treatment_name": "Mycophenolate mofetil", "treatment_type": "Immunosuppressants", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "New Type treatment : Sirolimus", "treatment_id": 1204, "treatment_name": "Sirolimus", "treatment_type": "Immunosuppressants", "pharmacological_treatment": "Pharmacological treatment"}]